Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Pharma
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Angus Liu
Apr 22, 2024 10:55am
AZ's Alexion debuts short film highlighting NMOSD community
Apr 18, 2024 2:16pm
Amylyx to pull failed ALS drug from market, cut 70% of staff
Apr 4, 2024 10:06am
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
Enspryng falls short of Roche's expectations in myasthenia gravis
Mar 21, 2024 11:28am
Kyowa's Orchard hopes $4.25M gene therapy price tag bears fruit
Mar 20, 2024 10:40am